Effect of prohibitin on hepatitis C virus replication

Shi JuanJuan; Yang Ning; Zhang Xin; Wu FengPing; Li Mei; Gao Ning; Jia XiaoLi; Zhai Song; Dang ShuangSuo

doi:10.3969/j.issn.1001-5256.2016.09.019

Issue 9

Sep. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(9): 1729-1733

PDF( 1901 KB)

Effect of prohibitin on hepatitis C virus replication

DOI: 10.3969/j.issn.1001-5256.2016.09.019

Department of Infectious Diseases, The Second Affiliated Hospital of Xi′an Jiaotong University

Research funding:

Published Date: 2016-09-20

Abstract

Abstract

Objective To investigate the effect of prohibitin( PHB) on hepatitis C virus( HCV) replication. Methods Human hepatocarcinoma Huh- 7. 5 cells were transfected with the full- length genome HCV RNA in vitro to establish the full- length genome cell model of HCV,and the supernatants were collected 24,48,72,and 96 hours later to measure HCV copies. The indirect immunofluorescence assay was used to measure the expression of HCV core proteins,and a transmission electron microscope was used to observe the changes in the ultrastructure of HCV- infected Huh- 7. 5 cells and identify the full- length genome cell model of HCV. Quantitative real- time PCR and Western Blot were used to measure the expression of PHB in HCV- infected Huh- 7. 5 cells,and the RNA interference technique was used to measure the replication of HCV RNA. The t- test was used for comparison between groups. Results The results of identification showed that the HCV full- length genome cell model was successfully established. At 24 and 48 hours after Huh- 7. 5 cells were transfected with HCV RNA,the mRNA expression level of PHB was 13. 41 ± 1. 35 and 16. 45 ± 1. 76,respectively,which differed significantly from that in the control group( 1. 01 ± 0. 57 and 1. 01 ± 0. 87,t = 29. 540 and 31. 361,both P < 0. 01),and the 24- and 48- hour transfection groups showed a significantly higher expression level of PHB than the control group( both P < 0. 01). At 24 and 48 hours after Huh- 7. 5 cells were transfected with the RNA interference plasmids of PHB,the level of HCV RNA was 64. 32 ± 5. 49 and 84. 45 ± 7. 06,respectively,significantly higher than that in the control group( shRNA- control group; 10. 52 ± 1. 57 and 16. 34 ± 2. 97,t = 29. 538 and 25. 908,all P < 0. 01).Conclusion In HCV- infected Huh- 7. 5 cells,the increased expression of PHB is closely related to HCV RNA infection,and to a certain extent,PHB can inhibit the replication of HCV RNA.
- hepacivirus,
- cell line,tumor,
- inhibins,
- RNA interference

FullText(HTML)

References(17)

References

[1]RIZWANI W,ALEXANDROW M,CHELLAPPAN S.Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication[J].Cell Cycle,2009,8(10):1621-1629.

[2]THEISS AL,SITARAMAN SV.The role and therapeutic potential of prohibitin in disease[J].Biochim Biophys Acta,2011,1813(6):1137-1143.

[3]EMERSON V,HOLTKOTTE D,PFERIFFER T,et al.Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein[J].J Virol,2010,84(3):1355-1365.

[4]LOPEZ-HUERTAS MR,MATEOS E,SNCHEZ DEL COJO M,et al.The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+T lymphocytes:a potential mechanism for persistent viral production[J].J Biol Chem,2013,288(11):7626-7644.

[5]LIU C,ZHANG A,GUO J,et al.Identification of human host proteins contributing to H5N1 influenza virus propagation by membrane proteomics[J].J Proteome Res,2012,11(11):5396-5405.

[6]ROGEE S,LE GALL M,CHAFEY P,et al.Quantitative proteomics identifies host factors modulated during acute hepatitis E virus infection in the swine model[J].J Virol,2015,89(1):129-143.

[7]LIU S,WANG W,BROWN LE,et al.A novel class of small molecule compounds that inhibit hepatitis C virus infection by targeting the prohibitin-CRaf pathway[J].EBio Medicine,2015,2(11):1600-1606.

[8] SUN MZ,DANG SS.Research progress of prohibitin in liver disease[J/CD].Chin J Liver Dis:Electronic Edition,2011,3(2):61-64.(in Chinese)孙明珠,党双锁.抗增殖蛋白在肝脏疾病中的研究进展[J/CD].中国肝脏病杂志:电子版,2011,3(2):61-64.

[9]TSUTSUMI T,MATSUDA M,AIZAKI H,et al.Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon,prohibitin,in cells expressing hepatitis C virus core protein[J].Hepatology,2009,50(2):378-386.

[10]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342.

[11]LINDENBACH BD,EVANS MJ,SYDER AJ,et al.Complete replication of hepatitis C virus in cell culture[J].Science,2005,309(22):623-626.

[12]QIAN X,XU C,ZHAO P,et al.Long non-coding RNA GAS5inhibited hepatitis C virus replication by binding viral NS3 protein[J].Virology,2016,492:155-165.

[13]LIU S,HAO Q,PENG N,et al.Major vault protein:a virus-induced host factor against viral replication through the induction of type-Ⅰinterferon[J].Hepatology,2012,56(1):57-66.

[14]SANCHEZ-QUILES V,SANTAMARIA E,SEQURA V,et al.Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells:molecular mechanisms and functional implications[J].Proteomics,2010,10(8):1609-1620.

[15]CHENG J,GAO F,CHEN X,et al.Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy[J].Mol Carcinog,2014,53(10):820-832.

[16] DANG SS,SUN MZ,XUN M,et al.Expression of prohibitin in hunman liver cancer cells SMMC-7721 and Huh-7 and amplification of prohibitin coding sequence[J/CD].Chin J Liver Dis:Electronic Edition,2010,2(3):1-5.(in Chinese)党双锁,孙明珠,寻萌,等.抑制素在人肝癌细胞SMMC-7721和Huh-7中的表达及其编码序列扩增[J/CD].中国肝脏病杂志:电子版,2010,2(3):1-5.

[17]ZHAO W,WANG L,CHEN P,et al.7-aa peptide mimic from HVR1 of HCV protects hepatic injury in rats by reduced expression of key pro-inflammatory factors[J].Inflamm Allergy Drug Targets,2010,9(2):135-145.

Relative Articles

[1]	Jingjie ZHAO, Xinyu ZHAO, Chaoru HAN, Kaihui XIAO, Zhengzhao LU, Linyan QIN, Dong XU, Hong YOU. Association between sleep disorders and different stages of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(7): 1354-1359. doi: 10.12449/JCH240712
[2]	Yuzhen YU, Liewang QIU, Ping HE. Association between Helicobacter pylori and nonalcoholic fatty liver disease： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1360-1369. doi: 10.12449/JCH240713
[3]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[4]	Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG. Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1106-1113. doi: 10.3969/j.issn.1001-5256.2022.05.025
[5]	Zhiran YANG, Linheng WANG, Yuan LI, Fusheng LIU, Yu WANG, Jianfang WANG, Runhua CHEN. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 97-103. doi: 10.3969/j.issn.1001-5256.2022.01.015
[6]	Jincheng WANG, Peihe YU, Song SU, Bo LI. Clinical effect of endoscopic nasobiliary drainage versus endoscopic biliary stenting in preoperative biliary drainage for low-level malignant obstructive jaundice: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(4): 863-867. doi: 10.3969/j.issn.1001-5256.2021.04.027
[7]	Shuping CHENG, Ming LI, Qingyu ZHANG, Shiyun TAN. Efficacy and safety of rifaximin in the prevention of spontaneous bacterial peritonitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(2): 318-325. doi: 10.3969/j.issn.1001-5256.2021.02.015
[8]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[9]	Huaqiang ZHANG, Lixin LIU, Xiaohong GUO. Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1619-1625. doi: 10.3969/j.issn.1001-5256.2021.07.028
[10]	Tingpeng HU, Sudan TANG, Zebo YU. Relationship between vitamin D level in children and adolescents with nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(3): 627-631. doi: 10.3969/j.issn.1001-5256.2021.03.024
[11]	Li XiaoJing, Sun YuanLong, Zhang BinBin, Mei ZuBing, Feng Qin, Hu YiYang. Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(10): 2241-2247. doi: 10.3969/j.issn.1001-5256.2020.10.016
[12]	Liu ShenShen, Xing YiQing, Wang Ning, Yu QiaoLing, Ceng LePing. Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1545-1550. doi: 10.3969/j.issn.1001-5256.2020.07.019
[13]	Huang ZhiPeng, Jiang JianJia, Huang ZiCheng, Guo GuiYuan, Zhou APei, Liu XiaoQiang. Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area[J]. Journal of Clinical Hepatology, 2019, 35(5): 1061-1064. doi: 10.3969/j.issn.1001-5256.2019.05.025
[14]	Chang Yue, Zhang Wen, Liu QinYu, Zhang Qing, Chen Kai, Li Hai. Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1057-1060. doi: 10.3969/j.issn.1001-5256.2019.05.024
[15]	Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
[16]	Tan YanXin, Long FuLi, Mao DeWen, Zhang JianLing, Ma YuZhen, Yan LianJie. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2266-2271. doi: 10.3969/j.issn.1001-5256.2019.10.027
[17]	Tao LiNa, Qu XiaoYu, Zhang Yue, Song YanQing, Zhang SiXi. Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials[J]. Journal of Clinical Hepatology, 2019, 35(8): 1775-1781. doi: 10.3969/j.issn.1001-5256.2019.08.025
[18]	Lai Li, Peng FangYi, Su Song, Fang Cheng, Zhang MengYu, He Kai, Li Bo, He Pan, Xia XianMing. Clinical effect of robotic versus laparoscopic splenectomy in treatment of nontraumatic splenic diseases:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2281-2285. doi: 10.3969/j.issn.1001-5256.2019.10.030
[19]	Chen ZhiHui, Zhang ShiRong, Sun WenJing, Wen LiangZhi, Liu KaiJun, Guo Yan, Wei YanLing, Wang Bin, Gu XiaoHong, Chen DongFeng. A clinical study of pulmonary function changes in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(4): 825-828. doi: 10.3969/j.issn.1001-5256.2018.04.026
[20]	Hou Jie, Liu LiXin. Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2624-2630. doi: 10.3969/j.issn.1001-5256.2018.12.023

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 徐家文，徐文杰. 从“五脏相关”学说论治代谢相关脂肪性肝病. 中国实用乡村医生杂志. 2024(04): 10-13 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2071) PDF downloads(437)

Effect of prohibitin on hepatitis C virus replication

DOI: 10.3969/j.issn.1001-5256.2016.09.019

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of prohibitin on hepatitis C virus replication

DOI: 10.3969/j.issn.1001-5256.2016.09.019

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content